He further explained he was diagnosed with a slow-growing "bone marrow cancer" called Waldenström's macroglobulinemia (WM): "Unfortunately, there's no cure for it. So that weighs heavily in every ...

Pharming's Phase 3 trial results for leniolisib in children with APDS demonstrate efficacy and safety, supporting future ...

Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc's, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the ...